ArticleScientific reports2025
Molecular profiling of endometrial cancer in Martinique reveals frequent CCNE1 amplification in poor prognosis tumors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility ofCancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn Martinique, there is an unmet need in EC management. Although the incidence rate is similar to that in mainland France, the mortality rate is higher, potentially due to the over-incidence of high-grade tumors. Recently, we reported CCNE1 amplification in 70% of these tumors which have a poor prognosis. This alteration has been observed in non-endometrioid subtypes of African American women. To elucidate the over-incidence of poor prognosis EC in Martinique, we aim to describe molecular profiles especially CCNE1 amplification of a cohort of all patient diagnosed between January 2023 and June 2024.
methodsCCNE1 amplification status was determined using digital PCR. We also performed the analysis of POLE, MMR and TP53 to classified tumors in current molecular classification. A total of 55 patients were included in our study, revealing a different distribution of biomarkers than described in the literature.
resultsWe reported an over-incidence of TP53 mutations and CCNE1 amplification. Conversely, the prevalence of POLE mutations was lower. In this study, non-endometrioid subtypes were particularly associated with CCNE1 amplification that is consistent with previous studies. The molecular classification observed in our cohort is consistent with findings in populations of African descent. The higher CCNE1 amplification rate mirrors those seen in these populations.
conclusionGiven the ethnic origin of the Martinique population, these data suggest that CCNE1 amplification may be linked to African genetic heritage and could explain the over-incidence of non-endometrioid subtypes in these populations. Furthermore, our study contributes to addressing racial disparities in endometrial cancer outcomes by providing crucial insights into the genetic factors that may influence the prognosis of African-descended populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.